

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1-88. (Canceled)

89. (Currently amended) A grafted antibody, or functional fragment thereof, wherein said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, wherein the heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8.

90. (Currently amended) An antibody, or functional fragment thereof, wherein said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein.

91. (New) The grafted antibody of claim 89, wherein said antibody or functional fragment thereof has a specific binding activity for a cryptic collagen epitope.

92. (New) The grafted antibody of claim 89, wherein said antibody or functional fragment thereof has at least a two-fold higher binding activity for denatured collagen over native collagen.

93. (New) The antibody of claim 90, wherein said antibody or functional fragment thereof has a specific binding activity for a cryptic collagen epitope.

94. (New) The antibody of claim 90, wherein said antibody or functional fragment thereof has at least a two-fold higher binding activity for denatured collagen over native collagen.

95. (New) The functional fragment of claim 89 or 90, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

96. (New) A nucleic acid encoding the antibody or functional fragment thereof of claim 89 or 90.

97. (New) The grafted antibody or functional fragment thereof of claim 89, wherein said grafted antibody, or functional fragment thereof, further comprises a therapeutic moiety.

98. (New) The grafted antibody or functional fragment thereof of claim 89, wherein said grafted antibody, or functional fragment thereof, further comprises a diagnostic moiety.

99. (New) The antibody or functional fragment thereof of claim 90, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.

100. (New) The antibody or functional fragment thereof of claim 90, wherein said antibody, or functional fragment thereof, further comprises a diagnostic moiety.

101. (New) A method of targeting angiogenic vasculature, comprising administering a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or

more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, the heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

102. (New) A method of targeting angiogenic vasculature, comprising administering an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID

NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

103. (New) The method of claim 101 or 102, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.

104. (New) The method of claim 101 or 102, wherein said antibody, or functional fragment thereof, further comprises a detectable moiety.

105. (New) A method of inhibiting angiogenesis, comprising administering a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, said heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

106. (New) A method of inhibiting angiogenesis, comprising administering an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

107. (New) The method of claim 105 or 106, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.

108. (New) A method of targeting a tumor, comprising administering a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, said heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

109. (New) A method of targeting a tumor, comprising administering an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

110. (New) The method of claim 108 or 109, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.

111. (New) The method of claim 108 or 109, wherein said antibody, or functional fragment thereof, further comprises a detectable moiety.

112. (New) A method of inhibiting tumor growth, comprising administering a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, said heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

113. (New) A method of inhibiting tumor growth, comprising administering an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

114. (New) The method of claim 112 or 113, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.

115. (New) A method of detecting angiogenic vasculature, comprising contacting angiogenic vasculature with a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative

substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, said heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

116. (New) A method of detecting angiogenic vasculature, comprising contacting angiogenic vasculature with an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

117. (New) The method of claim 115 or 116, wherein said antibody, or functional fragment thereof, further comprises a detectable moiety.

118. (New) A method of inhibiting metastasis, comprising administering a grafted antibody, or functional fragment thereof,

said grafted antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said grafted antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, said heavy chain CDRs are grafted into a VHIII/JH6 heavy chain variable region framework referenced as SEQ ID NO:8, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

119. (New) A method of inhibiting metastasis, comprising administering an antibody, or functional fragment thereof,

said antibody or functional fragment thereof comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR selected from the group consisting of SEQ ID NOS:26, 28 and 30 or a light chain CDR selected from the group consisting of SEQ ID NOS:20, 22 and 24, wherein

said antibody, or functional fragment thereof, comprises: a heavy chain CDR1 referenced as SEQ ID NO:45 or SEQ ID NO:45 having a conservative substitution therein; a heavy chain CDR2 referenced as SEQ ID NO:155 or SEQ ID NO:155 having a conservative substitution therein; a

heavy chain CDR3 referenced as SEQ ID NO:63 or SEQ ID NO:63 having a conservative substitution therein; a light chain CDR1 referenced as SEQ ID NO:157 or SEQ ID NO:157 having a conservative substitution therein; a light chain CDR2 referenced as SEQ ID NO:22 or SEQ ID NO:22 having a conservative substitution therein; and a light chain CDR3 referenced as SEQ ID NO:77 or SEQ ID NO:77 having a conservative substitution therein, and

said antibody or functional fragment thereof having specific binding activity for a cryptic collagen epitope.

120. (New) The method of claim 118 or 119, wherein said antibody, or functional fragment thereof, further comprises a therapeutic moiety.